

Codex Alimentarius Commission

40th Session

Geneva, 17 – 22 July 2017

**European Union comments on the
Proposed draft MRLs for lasalocid sodium, ivermectin and teflubenzuron
at step 5/8
(CL 2016/38-RVDF)**

European Union Competence

European Union Vote

 **Lasalocid sodium**

The European Union (EU) would like to reiterate its reservation to the adoption of the proposed draft MRLs for lasalocid sodium at step 5/8.

The EU considers that a risk to consumers cannot be ruled out, as in the absence of a methodology for derivation of a microbiological acute reference dose, there is no health-based guidance value with which to satisfactorily compare the acute exposure.

 **Ivermectin**

1. Proposed Draft MRL for ivermectin for muscle

The EU can support the proposed draft MRL.

2. Proposed draft MRLs for ivermectin for fat, kidneys and liver

The EU does not object to the proposed draft MRLs for ivermectin in fat, kidneys and liver.

 **Teflubenzuron**

The EU does not object to the proposed draft MRLs for teflubenzuron.